# EQRx (stock symbol: EQRX) Logo in transparent PNG and SVG formats

## EQRx Logo large

### EQRx Logo large Download PNG (22.73 KB)

![EQRx Logo large Download PNG (22.73 KB)](/img/orig/EQRX_BIG-6e91e967.png)

### EQRx Logo large Download SVG (1.28 KB)

![EQRx Logo large Download SVG (1.28 KB)](/img/orig/EQRX_BIG-48c729e7.svg)

## EQRx Logo icon format

### EQRx Logo icon format Download PNG (23.93 KB)

![EQRx Logo icon format Download PNG (23.93 KB)](/img/orig/EQRX-57fcb58e.png)

### EQRx Logo icon format Download SVG (993 Bytes)

![EQRx Logo icon format Download SVG (993 Bytes)](/img/orig/EQRX-6e25aff9.svg)

## EQRx Logo large for dark backgrounds

### EQRx Logo large for dark backgrounds Download PNG (22.73 KB)

![EQRx Logo large for dark backgrounds Download PNG (22.73 KB)](/img/orig/EQRX_BIG.D-f6597288.png)

### EQRx Logo large for dark backgrounds Download SVG (1.28 KB)

![EQRx Logo large for dark backgrounds Download SVG (1.28 KB)](/img/orig/EQRX_BIG.D-3b361a3a.svg)

## EQRx Logo icon format for dark backgrounds

### EQRx Logo icon format for dark backgrounds Download PNG (23.93 KB)

![EQRx Logo icon format for dark backgrounds Download PNG (23.93 KB)](/img/orig/EQRX.D-63433469.png)

### EQRx Logo icon format for dark backgrounds Download SVG (993 Bytes)

![EQRx Logo icon format for dark backgrounds Download SVG (993 Bytes)](/img/orig/EQRX.D-c49fad0a.svg)

## About EQRx

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

1. Website domain: eqrx.com
2. Employees: 240
3. Marketcap: $0.82 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
